세포치료 제조 시장(제7판) : 세포치료 유형별, 세포 기원별, 세포 유래별, 기술별, 사업 규모별, 제조업체 유형별, 주요 지역별 - 동향과 예측(-2035년)

CELL THERAPY MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global cell therapy manufacturing market is estimated to grow from USD 7.2 billion in the current year to USD 14.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 7.7% during the forecast period.

Cell Therapy Manufacturing Market: Growth and Trends

Cell-based therapies have emerged as one of the most clinically transformative modalities in modern medicine. There are more than 1,000 cell and gene therapy candidates under active investigation, and close to 45 cell-based therapies have already been approved by regulatory authorities worldwide. As the treatment class matures from a patient-specific intervention into a scalable therapeutic category, developers are increasingly shifting to specialized manufacturing partners to increase cell therapy production.

The industry is undergoing a decisive shift toward closed, automated, and standardized manufacturing platforms intended to reduce manual intervention, improve batch-to-batch consistency, and support scale-out production models.

Further, the tariff exposure on pharmaceutical imports has accelerated investment in domestic advanced-therapy manufacturing infrastructure in the US, while emerging economies including India and Saudi Arabia are building local capacity to support affordable, regionally accessible cell therapy production. Collectively, these initiatives point to a market that is shifting from artisanal manufacturing toward a more standardized, distributable, and investable industrial category.

Growth Drivers: Factors Fueling Market Expansion

Growth in the cell therapy manufacturing market is being driven primarily by the rapidly expanding clinical pipeline. As of now, industry trackers identified over 2,100 gene therapy candidates (including genetically modified cell therapies such as CAR-T) and close to 1,000 non-genetically modified cell therapies in active development. This sustained pipeline expansion is translating directly into demand for specialized clinical and commercial scale manufacturing capacity.

Furthermore, companies focused on affordable cell therapy access, together with government-backed facility investments in markets such as India and Saudi Arabia, are extending manufacturing capacity beyond the traditional North American and European hubs. This initiative is widening the addressable market for equipment, consumables, and logistics partners over the long term.

Market Challenges: Critical Barriers Hindering Progress

Despite favourable demand fundamentals, the market faces several challenges that impede growth. The transition of cell-based therapies from laboratory to commercial scale is constrained by a shortage of skilled bioprocessing professionals, evolving regulatory requirements, and limited GMP manufacturing capacity.

Further, scale-up remains a key challenge as cell therapy manufacturing requires GMP-compliant cleanrooms and strict quality controls, increasing costs, timelines, and manufacturing complexity. Addressing these workforce, infrastructure, and regulatory harmonization gaps will be central to unlocking the market's full commercial potential.

Role of Tariffs on Domestic Production

Tariff measures on pharmaceutical imports have prompted a wave of agreements and capital commitments aimed at expanding US-based manufacturing. In May, the US Commerce Department opened an application process allowing pharmaceutical manufacturers to seek reduced Section 232 tariff rates in exchange for committing to expand or relocate manufacturing operations domestically. This policy shift is expected to reinforce continued investment in onshore advanced-therapy manufacturing infrastructure.

Cell Therapy Manufacturing Market: Key Insights

The report delves into the current state of the Cell Therapy Manufacturing market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key findings include:

• Clinical Pipeline Momentum: Over 2,000+ active clinical trials are advancing cell therapies globally, sustaining long-term demand for clinical and commercial manufacturing capacity.
• Manufacturing Partnerships Accelerating: More than 150 strategic collaborations have been announced in the past five years, primarily focused on manufacturing, process development, and technology integration.
• Capacity Expansion Remains a Key Growth Strategy: Leading CDMOs and biopharma companies continue to invest in new GMP manufacturing facilities across North America, Europe, and Asia-Pacific to address anticipated commercial demand.
• Automation Gaining Traction: Increasing adoption of closed-system and automated manufacturing platforms is improving scalability, reducing contamination risk, and lowering manufacturing costs.
• Shift Toward Allogeneic Manufacturing: While autologous therapies currently dominate manufacturing demand, allogeneic cell therapies are expected to witness faster adoption owing to their off-the-shelf production potential.
• Oncology Continues To Lead: Oncology remains the largest therapeutic focus, accounting for the majority of cell therapy clinical programs, with autoimmune and neurological disorders emerging as high-growth application areas.
• North America Maintains Leadership: The region continues to account for the largest share of manufacturing activity, supported by a strong developer base, established CDMOs, and favourable investment ecosystem.
• Investment Activity Remains Robust: Venture capital funding, strategic acquisitions, and government support continue to strengthen manufacturing infrastructure and accelerate commercialization of advanced cell therapies.

Cell Therapy Manufacturing Market Segments

Roots Analysis segments the global cell therapy manufacturing market opportunity across the following parameters:

By Type of Cell Therapy

• CAR-T Cell Therapies
• Stem Cell Therapies
• TCR Therapies
• TIL Therapies
• Dendritic Cell Therapies
• Other Cell Therapies

By Source of Cells

• Autologous Cells
• Allogeneic Cells

By Origin of Cells

• Induced Pluripotent Stem Cells
• Bone Marrow
• Umbilical Cord
• Adipose Tissue
• Neural Stem Cells
• Others

By Technology

• Somatic Cell Technology
• 3D Bioprinting Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology

By Scale of Operation

• Clinical Scale
• Commercial Scale

By Type of Manufacturer

• In-house Manufacturers
• Contract Manufacturing Organizations

By Key Geographical Regions

• North America
• US
• Canada
• Europe
• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe
• Asia-Pacific and Rest of the World
• Argentina
• Australia
• Brazil
• China
• India
• Israel
• Japan
• Singapore
• South Africa
• South Korea
• Taiwan

Cell Therapy Manufacturing Market: Key Segment Insights

CAR-T Cell Therapies Lead the Market

Based on Roots Analysis market assessment and detailed clinical pipeline analysis, CAR-T cell therapies currently hold the highest share of the market. This dominance is driven by strong clinical and commercial adoption in hematological malignancies, an expanding portfolio of approved products, and the complex manufacturing processes associated with CAR-T therapies, which contribute significantly to overall market value.

Looking ahead, the other cell therapies segment including natural killer (NK) cell and genetically modified cell therapies will register the highest CAGR during the forecast period. This growth is driven by rising investment in next-generation cell therapy platforms designed to improve manufacturing scalability, reduce production costs, and expand patient access. Among these, natural killer (NK) cell therapies are gaining significant momentum owing to their allogeneic potential, favorable safety profile, lower risk of graft-versus-host disease, and suitability for off-the-shelf manufacturing.

Autologous Cells Continue to Dominate Source of Cells

According to our market analysis, autologous cells account for the largest share of the market and also register the highest CAGR during the forecast period. This growth is driven by the strong clinical adoption of patient-specific therapies, particularly within CAR-T manufacturing. Since autologous therapies use a patient's own cells, they reduce the risk of immune rejection and graft-versus-host disease. Recent approvals of autologous stem-cell-based gene therapies reinforce the continued clinical relevance of this approach.

Bone Marrow Leads Origin of Cells, iPSCs Poised for Fastest Growth

Bone marrow-derived cells currently account for the largest share of the market by origin of cells. This dominance is due to their long-established use in hematopoietic stem cell transplantation and well-defined collection, processing, and storage protocols. However, induced pluripotent stem cells (iPSCs) are expected to witness the strongest growth over the forecast period. This lucrative growth is due to their capacity to propagate indefinitely and differentiate into multiple specialized cell types, a property well suited to standardized, allogeneic, off-the-shelf manufacturing models.

Somatic Cell Technology Dominates, 3D Bioprinting Registers Higher CAGR

Somatic cell technology currently captures the largest share of the market. This highest share is due to its widespread use across isolation, processing, expansion, and modification workflows for CAR-T, TCR, dendritic cell, and stem cell based therapies. 3D bioprinting technology is expected to grow at the highest rate of any technology segment, driven by rising interest in personalized, tissue-mimetic cell-laden constructs for next-generation regenerative medicine applications.

Clinical-Scale Manufacturing Leads the Market While Commercial Scale Register Higher CAGR

Clinical-scale manufacturing currently captures the largest share of the market, reflecting the sheer volume of candidates still progressing through early and late stage trials. As more cell therapies advance toward approval and commercial launch, commercial-scale manufacturing capacity is expected to expand at a higher CAGR in the future, requiring sustained capital investment in cleanroom infrastructure and automation.

Contract Manufacturing Organizations Capture the Majority Share

CDMOs currently account for the majority of overall market revenue share. Outsourcing enables developers to reduce capital expenditure, accelerate clinical and commercial timelines, access advanced manufacturing technologies, and navigate complex regulatory requirements more efficiently. In contrast, in-house manufacturing remains concentrated among large, vertically integrated cell therapy companies with financial resources and technical expertise to establish and operate dedicated GMP-compliant manufacturing facilities.

North America Dominates the Market and Registers the Highest CAGR

North America currently captures the largest share of the cell therapy manufacturing market. This highest share is supported by a dense concentration of cell therapy developers, advanced GMP manufacturing infrastructure, established clinical research networks, and an increasingly flexible regulatory environment in the US. The region is also expected to register the fastest CAGR over the forecast period. This unprecedented growth is driven by continued capacity expansion including large-scale facility investments announced by both emerging and established players seeking next-generation manufacturing footprint in the US Northeast.

Example Players in Cell Therapy Manufacturing Market

• Advanced Therapies
• AGC Biologics
• Astellas Pharma
• Catalent
• Charles River Laboratories
• City of Hope
• Clinical Cell and Vaccine Production Facility (CVPF)
• Evotec
• Fraunhofer Institute for Cell Therapy and Immunology
• ImmunityBio
• Lonza
• Merck Millipore
• Miltenyi Biotec
• Minaris Advanced Therapies
• Newcastle Advanced Therapies
• NHS Blood and Transplant
• OBiO Tech
• Pharmaron
• Rayne Cell Therapy Suite
• Resilience
• Sartorius
• Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
• SK pharmteco (Subsidiary of SK Inc.)
• Takara Bio
• Thermo Fisher Scientific

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer, Mid-sized Company, UK
• Group Executive, Bioprocess, Very Large Company, US
• Former Chief Technical Officer, Large Company, US
• Vice President & Head of Quality & Compliance, Mid-sized Company, US
• Executive Director, Global Scientific Portfolio Management, Cell and Gene Therapy, Very Large Company, US
• Professor and American Red Cross Chair in Transfusion Medicine, US
• Senior Director of Sales, Advanced Therapies, Small Company, US
• Principal Scientist, Process Development Services, Very Large Company, Germany

CELL THERAPY MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth, top-down and bottom-up triangulated analysis of the market focusing on key segments, including type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer, and geographical regions.
• Industry and Non-Industry Player Landscape: A detailed assessment of both commercial (industry) and academic / non-profit (non-industry) cell therapy manufacturers, featuring year of establishment, company size, location of headquarters and manufacturing facilities, type of immune cell offered, source of cells, and scale of operation.
• Regulatory Landscape: A review of current regulatory guidelines across North America, Europe, and Asia-Pacific, including conditional approval pathways and the variability in requirements across geographies.
• Case Study I (Roadmaps for Overcoming Manufacturing Challenges): A focused assessment of roadmaps for cell processing, preservation, automation, quality control, standardization, workforce development, and supply chain across the US and other geographies.
• Case Study II (Automation Technologies): An evaluation of closed, single-use, and modular automation systems, including growth drivers, roadblocks, and case studies of automated manufacturing device development.
• Company Profiles: In-depth profiles of prominent industry and non-industry players, covering company overview, financial information, service portfolio, manufacturing facilities and capabilities, and recent developments.
• Non-Profit Organizations: An overview of non-profit and consortium-based cell therapy manufacturing initiatives and international societies active in the domain.
• Clinical Trial Analysis: A comprehensive analysis of cell therapy clinical trials by registration year, status, phase, study design, sponsor type, most active players, and geography.
• Partnerships and Collaborations: An analysis of partnerships inked by cell therapy manufacturers, based on year, type of partnership, type of immune cell, scale of operation, most active players, and geography.
• Recent Expansions Analysis: A comprehensive assessment of recent facility expansion initiatives by type, year, location, and immune cell focus, identifying the most active companies by number of expansions and area added.
• Big Pharma Initiatives: An analysis of initiatives undertaken by leading pharmaceutical companies, covering partnerships, M&A, facility expansions, and funding activity, and identifying the most active big pharma players.
• Capacity Analysis: A comprehensive assessment of global installed cleanroom capacity (number and area) across company size, scale of operation, and geography, for both industry and non-industry players.
• Demand Analysis: An evaluation of global clinical and commercial demand for cell therapy manufacturing, segmented by type of cell therapy and geography.
• Cost Price Analysis: An assessment of the factors driving high cell therapy pricing, pricing models, cost optimization levers, the role of CDMOs, and reimbursement considerations, including a NICE CAR-T appraisal case study.
• SWOT Analysis: A strategic assessment of the market's strengths, weaknesses, opportunities, and threats, with a comparative Harvey Ball analysis.
• Survey Analysis: Primary survey insights on respondent designation, type of cell therapy, scale of operation, source of cells, cell culture system, and fill / finish service availability.
• Executive Insights: Company snapshots and interview transcripts capturing the perspectives of senior industry and non-industry stakeholders.

Key Questions Answered in this Report

• Which are the leading companies in the cell therapy manufacturing market?
• Which region dominates the market, and which is growing the fastest?
• What are the key trends observed in this market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by cell therapy manufacturers?
• What is the current and future market size?
• What is the CAGR of this market through 2035?
• How is current and future market opportunity distributed across key segments?
• What opportunities exist for distributors and logistics partners entering this space?

Reasons to Buy this Report

This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the cell therapy manufacturing market.

• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, company-level capacity and demand data, minimizing forecast bias.
• 656 Pages Across 40 Chapters: Comprehensive coverage spanning market sizing, competitive benchmarking, clinical trial activity, capacity, demand, funding and M&A analysis, and regulatory mapping across 25+ countries.
• Primary Research-Backed Insights: Findings are validated through direct interviews with CEOs, CTOs, and commercial leaders across 34 industry and non-industry organizations, ensuring insights reflect real operating conditions rather than desk research alone.
• Actionable Segmentation: Seven-parameter segmentation (type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer, geography) enables precise opportunity sizing for any go-to-market or investment thesis.

Additional Benefits

• Complementary Insights Pack
• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Introduction to Cell-based Therapies
  • 6.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
  • 6.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
  • 6.2.3. Current Market Landscape of ATMPs
• 6.3. Overview of Cell Therapy Manufacturing
• 6.4. Cell Therapy Manufacturing Models
  • 6.4.1. Centralized Manufacturing
  • 6.4.2. Decentralized Manufacturing
• 6.5. Scalability of Cell Therapy Manufacturing Processes
  • 6.5.1. Scale-up
  • 6.5.2. Scale-out
• 6.6. Types of Cell Therapy Manufacturers
• 6.7. Key Challenges for Manufacturing Cell Therapies
• 6.8. Key Factors Influencing Cell Therapy Manufacturing
  • 6.8.1. Cell Characterization
  • 6.8.2. Cost of Goods
• 6.9. Automation of Cell Therapy Manufacturing
• 6.10. Cell Therapy Manufacturing Supply Chain
• 6.11. Future Perspectives

7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Industry Players: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters (Region)
  • 7.2.4. Analysis by Location of Headquarters (Country)
  • 7.2.5. Analysis by Company Size and Location of Headquarters (Region)
  • 7.2.6. Analysis by Location of Manufacturing Facility
  • 7.2.7. Analysis by Type of Immune Cell Offered
  • 7.2.8. Analysis by Source of Cells
  • 7.2.9. Analysis by Scale of Operation
  • 7.2.10. Analysis by Type of Additional Service Offered

8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Non-Industry Players: Overall Market Landscape
  • 8.2.1. Analysis by Year of Establishment
  • 8.2.2. Analysis by Location of Headquarters (Region)
  • 8.2.3. Analysis by Location of Headquarters (Country)
  • 8.2.4. Analysis by Location of Manufacturing Facility
  • 8.2.5. Analysis by Type of Immune Cell Offered
  • 8.2.6. Analysis by Source of Cell
  • 8.2.7. Analysis by Scale of Operation
  • 8.2.8. Analysis by Type of Additional Service Offered

9. REGULATORY LANDSCAPE

• 9.1. Chapter Overview
• 9.2. Current Scenario
  • 9.2.1. Regulatory Guidelines in North America
  • 9.2.2. Regulatory Guidelines in Europe
  • 9.2.3. Regulatory Guidelines in Asia-Pacific
    • 9.2.3.1. Regulatory Guidelines in Japan
    • 9.2.3.2. Regulatory Guidelines in China
  • 9.2.4. Conditional Approvals
• 9.3. Regulatory Authorities for Cell Therapy Manufacturing
  • 9.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
• 9.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
• 9.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
• 9.6. Variability in Regulatory Guidelines across Different Geographies

10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING

• 10.1. Chapter Overview
• 10.2. Roadmap for the US
  • 10.2.1. Cell Processing
  • 10.2.2. Cell Preservation, Distribution and Handling
  • 10.2.3. Process Automation and Data Analytics
  • 10.2.4. Process Monitoring and Quality Control
  • 10.2.5. Standardization and Regulatory Support
  • 10.2.6. Workforce Development
  • 10.2.7. Supply Chain and Logistics
• 10.3. Roadmaps for Other Geographies
  • 10.3.1. Europe
  • 10.3.2. Asia-Pacific

11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

• 11.1. Chapter Overview
• 11.2. Automation of Cell Therapy Manufacturing Processes
  • 11.2.1. Closed Systems
  • 11.2.2. Single-use Systems
  • 11.2.3. Modular Systems
• 11.3. Growth Drivers and Roadblocks
• 11.4. Case Studies
  • 11.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
  • 11.4.2. Automating the Cell Therapy Manufacturing Process
  • 11.4.3. Advancement to Automation of Cell Therapy Manufacturing Process
  • 11.4.4. GMP-in-a-Box
  • 11.4.5. List of Automated and Closed Cell Therapy Processing Systems

12. COMPANY PROFILES: INDUSTRY PLAYERS

• 12.1. Chapter Overview
• 12.2. Service Providers in North America
  • 12.2.1. Advanced Therapies
    • 12.2.1.1. Company Overview
    • 12.2.1.2. Financial Information
    • 12.2.1.3. Service Portfolio
    • 12.2.1.4. Manufacturing Facilities and Capabilities
    • 12.2.1.5. Recent Developments and Future Outlook
  • Similar details are presented for other below mentioned players based on information in the public domain
  • 12.2.2. AGC Biologics
  • 12.2.3. Catalent
  • 12.2.4. Charles River Laboratories
  • 12.2.5. ImmunityBio
  • 12.2.6. Merck Millipore
  • 12.2.7. Minaris Advanced Therapies
  • 12.2.8. Resilience
  • 12.2.9. SK pharmteco (Subsidiary of SK Inc.)
  • 12.2.10. Thermo Fisher Scientific
• 12.3. Service Providers in Europe
  • 12.3.1. Evotec
  • 12.3.2. Lonza
  • 12.3.3. Miltenyi Biotec
  • 12.3.4. Sartorius
• 12.4. Service Providers in Asia-Pacific
  • 12.4.1. Astellas Pharma
  • 12.4.2. OBiO Tech
  • 12.4.3. Pharmaron
  • 12.4.4. Takara Bio

13. COMPANY PROFILES: NON-INDUSTRY PLAYERS

• 13.1. Chapter Overview
• 13.2. City of Hope
  • 13.2.1. Overview
  • 13.2.2. Service Portfolio
  • 13.2.3. Type of Additional Service Offered
• similar details are presented for other below mentioned players based on information in the public domain
• 13.3. Clinical Cell and Vaccine Production Facility (CVPF)
• 13.4. Fraunhofer Institute for Cell Therapy and Immunology
• 13.5. Newcastle Advanced Therapies
• 13.6. NHS Blood and Transplant
• 13.7. Rayne Cell Therapy Suite (King's College London)
• 13.8. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility

14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

• 14.1. Chapter Overview
• 14.2. Cell Therapy Manufacturing: Non-Profit Organizations
  • 14.2.1. CellCAN
  • 14.2.2. Cell Therapy Manufacturing Cooperative Research Center
  • 14.2.3. National Cell Manufacturing Consortium (NCMC)
  • 14.2.4. California Institute of Regenerative Medicine (CIRM)
• 14.3. Cell Therapy Manufacturing: International Societies

15. CLINICAL TRIAL ANALYSIS

• 15.1. Chapter Overview
• 15.2. Scope and Methodology
• 15.3. Cell Therapies: Clinical Trial Analysis
  • 15.3.1. Analysis by Trial Registration Year
  • 15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
  • 15.3.3. Analysis by Trial Status
  • 15.3.4. Analysis by Trial Registration Year and Trial Status
  • 15.3.5. Analysis by Trial Phase
  • 15.3.6. Analysis of Enrolled Patient Population by Trial Phase
  • 15.3.7. Analysis by Patient Gender
  • 15.3.8. Analysis by Study Design
    • 15.3.8.1. Analysis by Type of Allocation
    • 15.3.8.2. Analysis by Intervention Model
    • 15.3.8.3. Analysis by Type of Masking
  • 15.3.9. Analysis by Type of Sponsor / Collaborator
  • 15.3.10. Most Active Players: Analysis by Number of Registered Trials
  • 15.3.11. Analysis by Geography
    • 15.3.11.1. Analysis of Clinical Trials by Geography
    • 15.3.11.2. Analysis of Clinical Trials by Trial Status and Geography
    • 15.3.11.3. Analysis of Enrolled Patient Population by Trial Status and Geography

16. PARTNERSHIPS AND COLLABORATIONS

• 16.1. Chapter Overview
• 16.2. Partnership Models
• 16.3. Cell Therapy Manufacturing: List of Partnerships
  • 16.3.1. Analysis by Year of Partnership
  • 16.3.2. Analysis by Type of Partnership
  • 16.3.3. Analysis by Year and Type of Partnership
• 16.4. Analysis by Type of Immune Cell Offered
• 16.5. Analysis by Scale of Operation
• 16.6. Most Active Players: Analysis by Number of Partnerships
• 16.7. Analysis by Geography
  • 16.7.1. Local and International Agreements
  • 16.7.2. Intracontinental and Intercontinental Agreements

17. RECENT EXPANSIONS

• 17.1. Chapter Overview
• 17.2. Type of Expansions
• 17.3. Cell Therapy Manufacturing: Recent Expansions
  • 17.3.1. Analysis by Year of Expansion
  • 17.3.2. Analysis by Type of Expansion
  • 17.3.3. Analysis by Year and Type of Expansion
  • 17.3.4. Analysis by Location of Expanded Facility (Region)
  • 17.3.5. Analysis by Location of Expanded Facility (Country)
  • 17.3.6. Analysis by Type of Expansion and Location of Headquarters (Country)
  • 17.3.7. Analysis by Type of Immune Cell Offered
  • 17.3.8. Analysis by Type of Expansion and Type of Immune Cell Offered
  • 17.3.9. Analysis by Scale of Operation
  • 17.3.10. Most Active Players: Analysis by Number of Expansions
  • 17.3.11. Most Active Players: Analysis by Area of Expansion

18. BIG PHARMA INITIATIVES

• 18.1. Chapter Overview
• 18.2. Cell Therapy Manufacturing: List of Big Pharma Players
• 18.3. Cell Therapy Manufacturing: List of Initiatives by Big Pharma Players
  • 18.3.1. Analysis by Year of Initiative
  • 18.3.2. Analysis by Type of Initiative
  • 18.3.3. Analysis by Year and Type of Initiative
  • 18.3.4. Big Players: Analysis by Number of Initiatives
  • 18.3.5. Analysis by Type of Partnership
  • 18.3.6. Big Players: Analysis by Number of Partnerships
  • 18.3.7. Analysis by Type of Facility Expansion
  • 18.3.8. Big Players: Analysis by Number of Facility Expansions
  • 18.3.9. Big Players: Analysis by Region of Facility Expansion
  • 18.3.10. Big Players: Analysis by Number of Mergers and Acquisitions
  • 18.3.11. Big Players: Analysis by Number of Funding and Investment
  • 18.3.12. Analysis by Type of Immune Cell Offered
  • 18.3.13. Analysis by Scale of Operation
  • 18.3.14. Analysis of Big Pharma Players by Scale of Operation
  • 18.3.15. Big Pharma Initiatives Summary

19. CAPACITY ANALYSIS

• 19.1. Chapter Overview
• 19.2. Industry Players: Key Assumptions and Methodology
  • 19.2.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
    • 19.2.1.1. Analysis by Company Size
    • 19.2.1.2. Analysis by Scale of Operation
    • 19.2.1.3. Analysis by Location of Manufacturing Facility
    • 19.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
    • 19.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
  • 19.2.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
    • 19.2.2.1. Analysis by Company Size
    • 19.2.2.2. Analysis by Scale of Operation
    • 19.2.2.3. Analysis by Location of Manufacturing Facility
    • 19.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
    • 19.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
• 19.3. Non-Industry Players: Key Assumptions and Methodology
  • 19.3.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
    • 19.3.1.1. Analysis by Scale of Operation
    • 19.3.1.2. Analysis by Location of Manufacturing Facility
  • 19.3.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
    • 19.3.2.1. Analysis by Scale of Operation
    • 19.3.2.2. Analysis by Location of Manufacturing Facility
• 19.4. Concluding Remarks

20. DEMAND ANALYSIS

• 20.1. Chapter Overview
• 20.2. Assumptions and Methodology
• 20.3. Global Demand for Cell Therapy Manufacturing
• 20.4. Global Clinical Demand for Cell Therapy Manufacturing
  • 20.4.1. Clinical Demand: Analysis by Type of Cell Therapy
  • 20.4.2. Clinical Demand: Analysis by Geography
• 20.5. Global Commercial Demand for Cell Therapy Manufacturing
  • 20.5.1. Commercial Demand: Analysis by Type of Cell Therapy
  • 20.5.2. Commercial Demand: Analysis by Geography

21. COST PRICE ANALYSIS

• 21.1. Chapter Overview
• 21.2. Factors Contributing to the High Price of Cell Therapies
• 21.3. Pricing Models for Cell Therapies
  • 21.3.1. Based on Associated Costs for T-cell Therapies
  • 21.3.2. Based on Associated Costs for Stem Cell Therapies
  • 21.3.3. Based on Availability of Competing Products
  • 21.3.4. Based on Target Patient Segment
  • 21.3.5. Based on the Opinions of Industry Experts
• 21.4. Cell Therapy Cost Optimization
  • 21.4.1. Role of Cost of Goods Sold
  • 21.4.2. Role of Automation
• 21.5. Role of Cell Therapy Contract Manufacturing Organizations
• 21.6. Reimbursement-related Considerations for Cell Therapies
  • 21.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 22.1. Chapter Overview
• 22.2. Assumptions and Key Parameters
• 22.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
  • 22.3.1. Scenario 1
  • 22.3.2. Scenario 2
  • 22.3.3. Scenario 3
  • 22.3.4. Scenario 4

23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

• 23.1. Chapter Overview
• 23.2. Key Parameters
• 23.3. Assumptions and Methodology
• 23.4. Sample Dataset for the Estimation of Total Cost of Ownership
• 23.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
• 23.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
  • 23.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
  • 23.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24. SWOT ANALYSIS

• 24.1. Chapter Overview
• 24.2. Strengths
• 24.3. Weaknesses
• 24.4. Opportunities
• 24.5. Threats
• 24.6. Comparison of SWOT Factors

25. SURVEY ANALYSIS

• 25.1. Chapter Overview
• 25.2. Analysis by Designation of Respondents
• 25.3. Analysis by Type of Cell Therapy
• 25.4. Analysis by Scale of Operation
• 25.5. Analysis by Source of Cells
• 25.6. Analysis by Type of Cell Culture System Used
• 25.7. Analysis by Availability of Fill / Finish Services

26. GLOBAL CELL THERAPY MANUFACTURING MARKET

• 26.1. Chapter Overview
• 26.2. Assumptions and Methodology
• 26.3. Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 26.4. Roots Analysis Perspective on Market Growth
• 26.5. Scenario Analysis
  • 26.5.1. Conservative Scenario
  • 26.5.2. Optimistic Scenario
• 26.6. Key Market Segmentations

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
  • 27.3.1. Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.2. Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.3. Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.4. Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.5. Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.6. Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 27.4. Data Triangulation and Validation

28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells
  • 28.3.1. Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 28.3.2. Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 28.4. Data Triangulation and Validation

29. CELL THERAPY MANUFACTURING MARKET, BY ORIGIN OF CELLS

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. Cell Therapy Manufacturing Market: Distribution by Origin of Cells
  • 29.3.1. Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 29.3.2. Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 29.3.3. Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 29.3.4. Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 29.3.5. Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 29.3.6. Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 29.4. Data Triangulation and Validation

30. CELL THERAPY MANUFACTURING MARKET, BY TECHNOLOGY

• 30.1. Chapter Overview
• 30.2. Key Assumptions and Methodology
• 30.3. Cell Therapy Manufacturing Market: Distribution by Technology
  • 30.3.1. Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 30.3.2. Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 30.3.3. Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 30.3.4. Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 30.3.5. Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 30.3.6. Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 30.4. Data Triangulation and Validation

31. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

• 31.1. Chapter Overview
• 31.2. Key Assumptions and Methodology
• 31.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation
  • 31.3.1. Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 31.3.2. Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 31.4. Data Triangulation and Validation

32. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

• 32.1. Chapter Overview
• 32.2. Key Assumptions and Methodology
• 32.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
  • 32.3.1. Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 32.3.2. Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 32.4. Data Triangulation and Validation

33. CELL THERAPY MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 33.1. Chapter Overview
• 33.2. Key Assumptions and Methodology
• 33.3. Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
  • 33.3.1. Clinical Cell Therapy Manufacturing Market
    • 33.3.1.1. Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.1.1. Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.1.2. Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 33.3.1.2. Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.2.1. Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.2.2. Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.2.3. Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.2.4. Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.2.5. Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 33.3.1.3. Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.1. Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.2. Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.3. Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.4. Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.5. Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.6. Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.7. Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.8. Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.1.3.9. Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 33.3.2. Commercial Cell Therapy Manufacturing Market
    • 33.3.2.1. Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.1.1. Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.1.2. Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 33.3.2.2. Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.2.1. Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.2.2. Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.2.3. Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.2.4. Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.2.5. Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.2.6. Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 33.3.2.3. Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.3.1. Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.3.2. Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.3.3. Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.3.4. Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.3.5. Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 33.3.2.3.6. Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 33.4. Penetration Growth (P-G) Matrix
• 33.5. Market Dynamics Assessment

34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 34.1. Cell Therapy Manufacturing Market in North America: Distribution by Type of Cell Therapy
  • 34.1.1. Cell Therapy Manufacturing Market in North America for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.1.2. Cell Therapy Manufacturing Market in North America for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.1.3. Cell Therapy Manufacturing Market in North America for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.1.4. Cell Therapy Manufacturing Market in North America for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.1.5. Cell Therapy Manufacturing Market in North America for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.1.6. Cell Therapy Manufacturing Market in North America for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 34.2. Cell Therapy Manufacturing Market in North America: Distribution by Source of Cells
  • 34.2.1. Cell Therapy Manufacturing Market in North America for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.2.2. Cell Therapy Manufacturing Market in North America for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 34.3. Cell Therapy Manufacturing Market in North America: Distribution by Origin of Cells
  • 34.3.1. Cell Therapy Manufacturing Market in North America for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.3.2. Cell Therapy Manufacturing Market in North America for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.3.3. Cell Therapy Manufacturing Market in North America for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.3.4. Cell Therapy Manufacturing Market in North America for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.3.5. Cell Therapy Manufacturing Market in North America for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.3.6. Cell Therapy Manufacturing Market in North America for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 34.4. Cell Therapy Manufacturing Market in North America: Distribution by Technology
  • 34.4.1. Cell Therapy Manufacturing Market in North America for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.4.2. Cell Therapy Manufacturing Market in North America for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.4.3. Cell Therapy Manufacturing Market in North America for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.4.4. Cell Therapy Manufacturing Market in North America for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.4.5. Cell Therapy Manufacturing Market in North America for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.4.6. Cell Therapy Manufacturing Market in North America for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 34.5. Cell Therapy Manufacturing Market in North America: Distribution by Scale of Operation
  • 34.5.1. Cell Therapy Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.5.2. Cell Therapy Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 34.6. Cell Therapy Manufacturing Market in North America: Distribution by Type of Manufacturer
  • 34.6.1. Cell Therapy Manufacturing Market in North America for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 34.6.2. Cell Therapy Manufacturing Market in North America for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)

35. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE

• 35.1. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Cell Therapy
  • 35.1.1. Cell Therapy Manufacturing Market in Europe for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.1.2. Cell Therapy Manufacturing Market in Europe for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.1.3. Cell Therapy Manufacturing Market in Europe for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.1.4. Cell Therapy Manufacturing Market in Europe for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.1.5. Cell Therapy Manufacturing Market in Europe for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.1.6. Cell Therapy Manufacturing Market in Europe for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 35.2. Cell Therapy Manufacturing Market in Europe: Distribution by Source of Cells
  • 35.2.1. Cell Therapy Manufacturing Market in Europe for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.2.2. Cell Therapy Manufacturing Market in Europe for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 35.3. Cell Therapy Manufacturing Market in Europe: Distribution by Origin of Cells
  • 35.3.1. Cell Therapy Manufacturing Market in Europe for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.3.2. Cell Therapy Manufacturing Market in Europe for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.3.3. Cell Therapy Manufacturing Market in Europe for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.3.4. Cell Therapy Manufacturing Market in Europe for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.3.5. Cell Therapy Manufacturing Market in Europe for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.3.6. Cell Therapy Manufacturing Market in Europe for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 35.4. Cell Therapy Manufacturing Market in Europe: Distribution by Technology
  • 35.4.1. Cell Therapy Manufacturing Market in Europe for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.4.2. Cell Therapy Manufacturing Market in Europe for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.4.3. Cell Therapy Manufacturing Market in Europe for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.4.4. Cell Therapy Manufacturing Market in Europe for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.4.5. Cell Therapy Manufacturing Market in Europe for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.4.6. Cell Therapy Manufacturing Market in Europe for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 35.5. Cell Therapy Manufacturing Market in Europe: Distribution by Scale of Operation
  • 35.5.1. Cell Therapy Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.5.2. Cell Therapy Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 35.6. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Manufacturer
  • 35.6.1. Cell Therapy Manufacturing Market in Europe for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 35.6.2. Cell Therapy Manufacturing Market in Europe for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)

36. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

• 36.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Cell Therapy
  • 36.1.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.1.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.1.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.1.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.1.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.1.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 36.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Source of Cells
  • 36.2.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.2.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 36.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Origin of Cells
  • 36.3.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.3.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.3.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.3.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.3.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.3.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 36.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Technology
  • 36.4.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.4.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.4.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.4.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.4.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.4.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 36.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
  • 36.5.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.5.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 36.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Manufacturer
  • 36.6.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 36.6.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• *Detailed information on Chapters 34-36 is available in the Excel Data Packs shared along with the report**

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

39. APPENDIX I: TABULATED DATA

40. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS